Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers

HIV Medicine

Volumn 8, Issue 7, 2007, Pages 457-464

  Luber, A D ^a,b,d   Brower, R ^b   Kim, D ^b   Silverman, R ^c   Peloquin, C A ^c   Frank, I ^b  

^a Private Practice   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d NONE   (United States)

Author keywords

Atazanavir; Fosamprenavir; Omeprazole

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; OMEPRAZOLE; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL; COMPARTMENT MODEL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG WITHDRAWAL; EYE JAUNDICE; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; STEADY STATE; VOLUNTEER; VOMITING;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CARBAMATES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; OLIGOPEPTIDES; OMEPRAZOLE; PHOSPHORIC ACID ESTERS; PROTON PUMP INHIBITORS; PYRIDINES; SULFONAMIDES;

EID: 34548299142     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00496.x     Document Type: Article

References (22)

1. Dieleman JP, Jambroes M, Gyssens IC et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort. AIDS 2002; 16: 737-745.
2. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34: 407-414.
3. Burgos A, Garrido J. Use of acid reducing agents among HIV infected patients receiving antiretrovirals in Spain. 10th European AIDS Conference. Dublin, Ireland, November 2005 [Abstract 4.3/5].
4. van Lunzen J, Arasteh K, Schuermann D. High proportion of patients taking concomitant protease-inhibitor (PI) containing HAART and gastric pH modifying agents - the Northern German HAART pH-blocker survey. 10th European AIDS Conference. Dublin, Ireland, November 2005 [Abstract 4.3/ 14].
5. Guessant S, Le Camus C, Lang J. Survey on the use of gastric acid-modifying medication in HIV-infected (HIV +) patients receiving antiretroviral (ARV) drugs in France. 10th European AIDS Conference. Dublin, Ireland, November 2005 [Abstract 4.6/1].
6. Luber AD, Garg V, Gharakhanian S. Survey of medications used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Abstract P294].
7. Adams C, Balkin A. Proton pump inhibitors (PPIs), antacids and histamine antagonists: What the patients do? 10th European AIDS Conference. Dublin, Ireland, November 2005 [Abstract 4.3/8].
8. Furfine ES, Baker CT, Hale MR et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother 2004; 48: 791-798.
9. Wood R, Arasteh K, Stellbrink HJ et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004; 48: 116-123.
10. Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother 2005; 49: 467-469.
11. Shelton MJ, Ford SL, Borland J et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006; 42: 61-67.
12. Omara E, Mummaneni V, Randall D et al. BMS-232632: A summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy volunteers. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2000 [Abstract 504].
13. Robinson BS, Riccardi KA, Gong YF et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44: 2093-2099.
14. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetics (PK) of omeprazole on atazanavir with ritonavir in healthy subjects. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 658].
15. Agarwala S, Eley T, Child M et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. 6th International Workshop on Pharmacology of HIV Therapy. Quebec City, Quebec, Canada, April 2005 [Abstract 11].
16. Guiard-Schmid J-B, Poirier J-M, Bonnard P et al. Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir. AIDS 2005; 19: 1937-1938.
17. Kosel BW, Storey SS, Collier AC. Lack of interaction between atazanavir and lansoprazole. AIDS 2005; 19: 637-638.
18. Eley T, Agarwala S, Wang R et al. Analysis of intra-gastric pH and atazanavir bioavailability in healthy subjects. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal, April 2006 [Abstract 93].
19. Lind T, Rydberg L, Kyleback A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-867.
20. Tomilo DL, Smith PF, Ogundele AB et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 2006; 26: 341-346.
21. Luber AD. Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes. AIDS Read 2005; 15: 698-700.
22. Ruane PJ, Luber AD, Wire MB et al. Plasma amprenavir phramokinetics and tolerability following administration of 1400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother 2007; 51: 560-565.